Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 6/2012

01.06.2012 | Article

Molecular characterization of Streptococcus pneumoniae invasive serotype 19A isolates from adults in two Spanish regions (1994–2009)

verfasst von: J. M. Marimón, M. Alonso, D. Rolo, C. Ardanuy, J. Liñares, E. Pérez-Trallero

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

From 1994 to 2009, the incidence of invasive serotype 19A pneumococci isolated from adults in Barcelona and San Sebastian almost doubled every 4 years. Genotyping of the 167 invasive isolates studied showed serotype 19A to be highly heterogeneous, with 35 different sequence types (STs) and a different clonal structure in each region and time period. Multiresistance, defined as non-susceptibility to three or more antimicrobials, was found in 86 (51.5%) isolates. The most frequent ST was the multidrug-resistant ST276 (n = 28), which is a single-locus variant of the Denmark14-ST230 global clone. The ST276 clone, only present in San Sebastian before 2001, was successfully disseminated from 2002 in both cities and was the main contributor to the overall increase of serotype 19A infections.
Literatur
1.
Zurück zum Zitat Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A; Active Bacterial Core Surveillance of the Emerging Infections Program Network (2003) Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348:1737–1746PubMedCrossRef Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A; Active Bacterial Core Surveillance of the Emerging Infections Program Network (2003) Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348:1737–1746PubMedCrossRef
2.
Zurück zum Zitat Centers for Disease Control and Prevention (CDC) (2005) Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease—United States, 1998–2003. MMWR Morb Mortal Wkly Rep 54:893–897 Centers for Disease Control and Prevention (CDC) (2005) Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease—United States, 1998–2003. MMWR Morb Mortal Wkly Rep 54:893–897
3.
Zurück zum Zitat Centers for Disease Control and Prevention (CDC) (2008) Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction—eight states, 1998–2005. MMWR Morb Mortal Wkly Rep 57:144–148 Centers for Disease Control and Prevention (CDC) (2008) Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction—eight states, 1998–2005. MMWR Morb Mortal Wkly Rep 57:144–148
4.
Zurück zum Zitat Choi EH, Kim SH, Eun BW, Kim SJ, Kim NH, Lee J, Lee HJ (2008) Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg Infect Dis 14:275–281PubMedCrossRef Choi EH, Kim SH, Eun BW, Kim SJ, Kim NH, Lee J, Lee HJ (2008) Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg Infect Dis 14:275–281PubMedCrossRef
5.
Zurück zum Zitat Harboe ZB, Benfield TL, Valentiner-Branth P, Hjuler T, Lambertsen L, Kaltoft M, Krogfelt K, Slotved HC, Christensen JJ, Konradsen HB (2010) Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades. Clin Infect Dis 50:329–337PubMedCrossRef Harboe ZB, Benfield TL, Valentiner-Branth P, Hjuler T, Lambertsen L, Kaltoft M, Krogfelt K, Slotved HC, Christensen JJ, Konradsen HB (2010) Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades. Clin Infect Dis 50:329–337PubMedCrossRef
6.
Zurück zum Zitat Ardanuy C, Rolo D, Fenoll A, Tarrago D, Calatayud L, Liñares J (2009) Emergence of a multidrug-resistant clone (ST320) among invasive serotype 19A pneumococci in Spain. J Antimicrob Chemother 64:507–510PubMedCrossRef Ardanuy C, Rolo D, Fenoll A, Tarrago D, Calatayud L, Liñares J (2009) Emergence of a multidrug-resistant clone (ST320) among invasive serotype 19A pneumococci in Spain. J Antimicrob Chemother 64:507–510PubMedCrossRef
7.
Zurück zum Zitat Pai R, Moore MR, Pilishvili T, Gertz RE, Whitney CG, Beall B; Active Bacterial Core Surveillance Team (2005) Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis 192:1988–1995PubMedCrossRef Pai R, Moore MR, Pilishvili T, Gertz RE, Whitney CG, Beall B; Active Bacterial Core Surveillance Team (2005) Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis 192:1988–1995PubMedCrossRef
8.
Zurück zum Zitat Moore MR, Gertz RE Jr, Woodbury RL, Barkocy-Gallagher GA, Schaffner W, Lexau C, Gershman K, Reingold A, Farley M, Harrison LH, Hadler JL, Bennett NM, Thomas AR, McGee L, Pilishvili T, Brueggemann AB, Whitney CG, Jorgensen JH, Beall B (2008) Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis 197:1016–1027PubMedCrossRef Moore MR, Gertz RE Jr, Woodbury RL, Barkocy-Gallagher GA, Schaffner W, Lexau C, Gershman K, Reingold A, Farley M, Harrison LH, Hadler JL, Bennett NM, Thomas AR, McGee L, Pilishvili T, Brueggemann AB, Whitney CG, Jorgensen JH, Beall B (2008) Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis 197:1016–1027PubMedCrossRef
9.
Zurück zum Zitat Mahjoub-Messai F, Doit C, Koeck JL, Billard T, Evrard B, Bidet P, Hubans C, Raymond J, Levy C, Cohen R, Bingen E (2009) Population snapshot of Streptococcus pneumoniae serotype 19A isolates before and after introduction of seven-valent pneumococcal vaccination for French children. J Clin Microbiol 47:837–840PubMedCrossRef Mahjoub-Messai F, Doit C, Koeck JL, Billard T, Evrard B, Bidet P, Hubans C, Raymond J, Levy C, Cohen R, Bingen E (2009) Population snapshot of Streptococcus pneumoniae serotype 19A isolates before and after introduction of seven-valent pneumococcal vaccination for French children. J Clin Microbiol 47:837–840PubMedCrossRef
10.
Zurück zum Zitat Muñoz-Almagro C, Esteva C, de Sevilla MF, Selva L, Gene A, Pallares R (2009) Emergence of invasive pneumococcal disease caused by multidrug-resistant serotype 19A among children in Barcelona. J Infect 59:75–82PubMedCrossRef Muñoz-Almagro C, Esteva C, de Sevilla MF, Selva L, Gene A, Pallares R (2009) Emergence of invasive pneumococcal disease caused by multidrug-resistant serotype 19A among children in Barcelona. J Infect 59:75–82PubMedCrossRef
11.
Zurück zum Zitat Tarragó D, Aguilar L, García R, Gimenez MJ, Granizo JJ, Fenoll A (2011) Evolution of clonal and susceptibility profiles of serotype 19A Streptococcus pneumoniae among invasive isolates from children in Spain, 1990 to 2008. Antimicrob Agents Chemother 55:2297–2302PubMedCrossRef Tarragó D, Aguilar L, García R, Gimenez MJ, Granizo JJ, Fenoll A (2011) Evolution of clonal and susceptibility profiles of serotype 19A Streptococcus pneumoniae among invasive isolates from children in Spain, 1990 to 2008. Antimicrob Agents Chemother 55:2297–2302PubMedCrossRef
12.
Zurück zum Zitat Aguiar SI, Pinto FR, Nunes S, Serrano I, Melo-Cristino J, Sá-Leão R, Ramirez M, de Lencastre H (2010) Denmark14-230 clone as an increasing cause of pneumococcal infection in Portugal within a background of diverse serotype 19A lineages. J Clin Microbiol 48:101–108PubMedCrossRef Aguiar SI, Pinto FR, Nunes S, Serrano I, Melo-Cristino J, Sá-Leão R, Ramirez M, de Lencastre H (2010) Denmark14-230 clone as an increasing cause of pneumococcal infection in Portugal within a background of diverse serotype 19A lineages. J Clin Microbiol 48:101–108PubMedCrossRef
13.
Zurück zum Zitat Beall BW, Gertz RE, Hulkower RL, Whitney CG, Moore MR, Brueggemann AB (2011) Shifting genetic structure of invasive serotype 19A pneumococci in the United States. J Infect Dis 203:1360–1368PubMedCrossRef Beall BW, Gertz RE, Hulkower RL, Whitney CG, Moore MR, Brueggemann AB (2011) Shifting genetic structure of invasive serotype 19A pneumococci in the United States. J Infect Dis 203:1360–1368PubMedCrossRef
14.
Zurück zum Zitat Pérez-Trallero E, Marimon JM, Ercibengoa M, Vicente D, Pérez-Yarza EG (2009) Invasive Streptococcus pneumoniae infections in children and older adults in the north of Spain before and after the introduction of the heptavalent pneumococcal conjugate vaccine. Eur J Clin Microbiol Infect Dis 28:731–738PubMedCrossRef Pérez-Trallero E, Marimon JM, Ercibengoa M, Vicente D, Pérez-Yarza EG (2009) Invasive Streptococcus pneumoniae infections in children and older adults in the north of Spain before and after the introduction of the heptavalent pneumococcal conjugate vaccine. Eur J Clin Microbiol Infect Dis 28:731–738PubMedCrossRef
15.
Zurück zum Zitat Marimon JM, Monasterio A, Ercibengoa M, Pascual J, Prieto I, Simón L, Perez-Trallero E (2010) Antibody microarray typing, a novel technique for Streptococcus pneumoniae serotyping. J Microbiol Methods 80:274–280PubMedCrossRef Marimon JM, Monasterio A, Ercibengoa M, Pascual J, Prieto I, Simón L, Perez-Trallero E (2010) Antibody microarray typing, a novel technique for Streptococcus pneumoniae serotyping. J Microbiol Methods 80:274–280PubMedCrossRef
16.
Zurück zum Zitat Clinical and Laboratory Standards Institute (CLSI) (2010) Performance standards for antimicrobial susceptibility testing: Twentieth Informational Supplement. CLSI document M100-S20. CLSI, Wayne, PA Clinical and Laboratory Standards Institute (CLSI) (2010) Performance standards for antimicrobial susceptibility testing: Twentieth Informational Supplement. CLSI document M100-S20. CLSI, Wayne, PA
17.
Zurück zum Zitat Reinert R, Jacobs MR, Kaplan SL (2010) Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine 28:4249–4259PubMedCrossRef Reinert R, Jacobs MR, Kaplan SL (2010) Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine 28:4249–4259PubMedCrossRef
Metadaten
Titel
Molecular characterization of Streptococcus pneumoniae invasive serotype 19A isolates from adults in two Spanish regions (1994–2009)
verfasst von
J. M. Marimón
M. Alonso
D. Rolo
C. Ardanuy
J. Liñares
E. Pérez-Trallero
Publikationsdatum
01.06.2012
Verlag
Springer-Verlag
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 6/2012
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-011-1399-3

Weitere Artikel der Ausgabe 6/2012

European Journal of Clinical Microbiology & Infectious Diseases 6/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.